In 2023, the liver cancer drugs market was valued at $2.67 billion. By 2032, it is expected to grow significantly, reaching $9.94 billion with an impressive compound annual growth rate (CAGR) of 14.2% from 2024 to 2032.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5146
The Central Drug Research Institute (CDRI), India, has made significant progress in liver cancer research through a collaborative study. The research focuses on the metabolic changes occurring in cells that could play a key role in preventing hepatocellular carcinoma (HCC), the most common type of liver cancer.
Conducted in partnership with CIMAP, CBMR, and CSIR-CDRI, the study highlights how cancer cells undergo a shift in metabolic programming. These alterations could pave the way for improved diagnostic and preventive strategies.
Led by Dr. Madhav Nilakanth Mugale of CSIR-CDRI, the research used an animal model to replicate the progression of HCC in humans. It identified critical changes associated with disease advancement, such as decreased body mass, elevated serum enzyme levels, and alterations in liver structure.
Published in the prestigious Elsevier journal, this study opens the door to developing targeted therapies based on metabolic reprogramming, offering hope for more effective treatments for liver cancer.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/liver-cancer-drugs-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5146
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The U.S. AI in healthcare market, valued at USD 11.57 billion in 2025, is projected to expand to USD 194.88… Read More
The global next-generation AI in life sciences market is witnessing rapid expansion, projected to reach several hundred million USD by… Read More
The U.S. oncology pharmaceutical market is poised for substantial growth, projected to generate hundreds of millions in revenue from 2025… Read More
The global autologous cell therapy market—valued at US$ 9.6 billion in 2024 and US$ 11.41 billion in 2025—is projected to… Read More
The U.S. biotechnology market is on a high-velocity growth path — from USD 699.02 billion in 2025 to USD 2,004.86… Read More
AI in Healthcare Market is projected to grow from USD 37.98 billion in 2025 to USD 674.19 billion by 2034… Read More